Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib

British Journal of Ophthalmology

Volumn 93, Issue 7, 2009, Pages 958-963

  Chung, E J ^a,b   Yoo, S ^b   Lim, H J ^c   Byeon, S H ^b   Lee, J H ^d   Koh, H J ^b  

^a National Health Insurance Corporation   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c EyeGene Inc   (South Korea)

^d Konyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME PHOSPHORYLATION; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; LASER COAGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; BENZENESULFONATES; BLOTTING, WESTERN; CHOROIDAL NEOVASCULARIZATION; DEXTRANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEINS; MICE; MICE, INBRED C57BL; PYRIDINES;

EID: 67649637107     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.149187     Document Type: Article

References (41)

1. Green WR. Histopathology of age-related macular degeneration. Mol Vis 1999;5:27.
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676 (Pubitemid 36749215)
3. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002;8:119-126 (Pubitemid 36153599)
4. Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-167 (Pubitemid 27129479)
5. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934 (Pubitemid 26324159)
6. Shen WY, Yu MJ, Barry CJ, et al. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularisation in the rat. Br J Ophthalmol 1998;82:1063-1071 (Pubitemid 28451280)
7. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996;80:363-366 (Pubitemid 26113591)
8. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995 (Pubitemid 24332901)
9. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997;67:353-366 (Pubitemid 27509471)
10. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-66. (Pubitemid 32553190)
11. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343 (Pubitemid 28545503)
12. Rousseau S, Houle F, Landry J, et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-2177 (Pubitemid 27493906)
13. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-2230 (Pubitemid 29186923)
14. Bikfalvi A, Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002;23:576-582 (Pubitemid 35375803)
15. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 2002;1:415-426 (Pubitemid 37361484)
16. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-693 (Pubitemid 36749217)
17. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-1295 (Pubitemid 36554699)
18. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18:338-340
19. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-2053 (Pubitemid 43825322)
20. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109 (Pubitemid 39331023)
21. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 1998;153:1641-1646 (Pubitemid 28509922)
22. Edelman JL, Castro MR. Quantitative image analysis of laser-induced choroidal neovascularization in rat. Exp Eye Res 2000;71:523-533 (Pubitemid 30947625)
23. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Invest Ophthalmol Vis Sci 1998;39:180-188 (Pubitemid 28040477)
24. Yanagi Y, Tamaki Y, Obata R, et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 2002;43:3495-3499 (Pubitemid 35334358)
25. Hood JD, Cheresh DA. Targeted delivery of mutant Raf kinase to neovessels causes tumor regression. Cold Spring Harb Symp Quant Biol 2002;67:285-291 (Pubitemid 36775522)
26. Rini BI. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 2007;13:1098-1106 (Pubitemid 46424048)
27. Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785-1792 (Pubitemid 46954055)
28. Murphy DA, Makonnen S, Lassoued W, et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006;169:1875-1885. (Pubitemid 351182016)
29. Diago T, Pulido JS, Molina JR, et al. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008;83:231-234 (Pubitemid 351303111)
30. Kernt M, Staehler M, Stief C, et al. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 2008;86:456-458
31. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816 (Pubitemid 40051904)
32. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431 (Pubitemid 44511557)
33. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38:1258-1264 (Pubitemid 38802172)
34. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346 (Pubitemid 34250056)
35. Kwak N, Okamoto N, Wood JM, et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158-3164 (Pubitemid 30691960)
36. Bullard LE, Qi X, Penn JS. Role for extracellular signal-responsive kinase-1 and -2 in retinal angiogenesis. Invest Ophthalmol Vis Sci 2003;44:1722-1731 (Pubitemid 36378603)
37. Hayashi A, Imai K, Kim HC, et al. Activation of protein tyrosine phosphorylation after retinal branch vein occlusion in cats. Invest Ophthalmol Vis Sci 1997;38:372-380 (Pubitemid 27085694)
38. Hayashi A, Koroma BM, Imai K, et al. Increase of protein tyrosine phosphorylation in rat retina after ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 1996;37:2146-2156 (Pubitemid 26338763)
39. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106. (Pubitemid 29062964)
40. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147 (Pubitemid 38524883)
41. Zhu WH, MacIntyre A, Nicosia RF. Regulation of angiogenesis by vascular endothelial growth factor and angiopoietin-1 in the rat aorta model: distinct temporal patterns of intracellular signaling correlate with induction of angiogenic sprouting. Am J Pathol 2002;161:823-830 (Pubitemid 34988369)